Clinical trial
Pilot Study of Redirected Autologous T Cells Transduced to Express A CD20-Specific Chimeric Immunoreceptor in Patient With Chemotherapy Resistant or Refractory CD20+ Leukemia and Lymphoma
NCT01735604 is registered in ClinicalTrials.gov with Chinese PLA General Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Pilot Study of Redirected Autologous T Cells Transduced to Express A CD20-Specific Chimeric Immunoreceptor in Patient With Chemotherapy Resistant or Refractory CD20+ Leukemia and Lymphoma
- Lead sponsor
- Chinese PLA General Hospital
- Phase
- Phase 1/2
- Overall status
- Unknown status
- Start date
- January 31, 2013
- Completion date
- October 31, 2018
- Enrollment
- 50 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
adult acute lymphoblastic leukemia in remission, b-cell adult acute lymphoblastic leukemia, b-cell chronic lymphocytic leukemia, hematopoietic/lymphoid cancer, prolymphocytic leukemia, recurrent adult diffuse large cell lymphoma, recurrent grade 1 follicular lymphoma, recurrent grade 2 follicular lymphoma, recurrent grade 3 follicular lymphoma, recurrent mantle cell lymphoma, refractory chronic lymphocytic leukemia, stage iii adult diffuse large cell lymphoma, stage iii chronic lymphocytic leukemia, stage iii grade 1 follicular lymphoma, stage iii grade 2 follicular lymphoma, stage iii grade 3 follicular lymphoma, stage iii mantle cell lymphoma, stage iv adult diffuse large cell lymphoma, stage iv chronic lymphocytic leukemia, stage iv grade 1 follicular lymphoma, stage iv grade 2 follicular lymphoma, stage iv grade 3 follicular lymphoma, stage iv mantle cell lymphoma